Anonymous
Guest
Anonymous
Guest
First half sales of VIMOVO(TM) (naproxen / esomeprazole magnesium) delayed-release tablets were $10.1 million; $6.3 million in Q2 2011.
• VIMOVO was launched in 5 additional European countries in the second quarter of 2011
So in the first 2 qtrs we sold 10.1 million dollars. This drug is on fire, and if AZ keeps selling it we may be putting a blank it on it to put out the fire. This drug is a dog.
In the second QTR there were on 6.3 million in total sales which i understand is obvious from the above information, but those numbers also include 5 additional countries in europe. So 10 million for a half a year in the US may actually be going in the wrong direction.
Please bring some water and put this fire out and kill it. What a waste of MCL reps at 40 percent market basket, and I dont know what the CNS division is doing with this drug. that is a lot of reps for 10 million dollars in total sales.
One other comment this is not how much they made in royalties this was total Vimovo sales. According to this same artical Pozen only made 600 k for the qtr.
Here is their quote from their financial statements on money made for pozen.
"for the second quarter of 2011, POZEN reported revenue of $4.6 million, comprised of royalty on sales of Treximet and VIMOVO, of $4.0 million and $0.6 million, respectively
This horse needs to go to the glue factory!!!!!!
• VIMOVO was launched in 5 additional European countries in the second quarter of 2011
So in the first 2 qtrs we sold 10.1 million dollars. This drug is on fire, and if AZ keeps selling it we may be putting a blank it on it to put out the fire. This drug is a dog.
In the second QTR there were on 6.3 million in total sales which i understand is obvious from the above information, but those numbers also include 5 additional countries in europe. So 10 million for a half a year in the US may actually be going in the wrong direction.
Please bring some water and put this fire out and kill it. What a waste of MCL reps at 40 percent market basket, and I dont know what the CNS division is doing with this drug. that is a lot of reps for 10 million dollars in total sales.
One other comment this is not how much they made in royalties this was total Vimovo sales. According to this same artical Pozen only made 600 k for the qtr.
Here is their quote from their financial statements on money made for pozen.
"for the second quarter of 2011, POZEN reported revenue of $4.6 million, comprised of royalty on sales of Treximet and VIMOVO, of $4.0 million and $0.6 million, respectively
This horse needs to go to the glue factory!!!!!!